The shadow of generic rivalry has long loomed around copyright’s blockbuster drug, Sildenafil, sparking questions about the prospects of similar pharmaceutical portfolios. While initial years saw significant gains, the intellectual property expiration has created the path for cheaper substitutes, likely reducing profitability and posing a signifi